National Cancer Institute Central IRBAugust 9, 2022

FDA 483 - National Cancer Institute Central IRB - August 09, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

An FDA inspection of the National Cancer Institute Central IRB in Rockville, MD, revealed a significant procedural lapse. The Institutional Review Board failed to update its registration information regarding changes in chairperson within the required 90-day timeframe. This resulted in delays of 467 and 106 days for two separate IRB committees.

Company: National Cancer Institute Central IRB
Inspection Date: August 9, 2022
Product Type: Other
Office: Office of Regulatory Affairs
Person: David L. Chon (Consumer Safety Officer/BIMO Investigator)

Open in Dashboard

ID · 34541808-bed8-418e-862d-d3b4628a3d0b